• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Receiving CAR T-cells gets faster, but not for all in need.

作者信息

Ramos Kristie N, Auletta Jeffery J

机构信息

Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.

Center for International Blood and Marrow Transplant Research, NMDP, Minneapolis, MN.

出版信息

Blood Adv. 2025 Jan 28;9(2):436-438. doi: 10.1182/bloodadvances.2024015013.

DOI:10.1182/bloodadvances.2024015013
PMID:39874028
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11846599/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a56/11846599/f2228a6c31aa/BLOODA_ADV-2024-015013-C-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a56/11846599/f2228a6c31aa/BLOODA_ADV-2024-015013-C-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a56/11846599/f2228a6c31aa/BLOODA_ADV-2024-015013-C-gr1.jpg

相似文献

1
Receiving CAR T-cells gets faster, but not for all in need.接受嵌合抗原受体（CAR）T细胞治疗的过程加快了，但并非所有有需要的人都能如此。
Blood Adv. 2025 Jan 28;9(2):436-438. doi: 10.1182/bloodadvances.2024015013.
2
Incidence of Acute Kidney Injury in Relapsed and Refractory Multiple Myeloma treated with Teclistamab versus CAR T-cells.用替西妥单抗与嵌合抗原受体 T 细胞治疗复发难治性多发性骨髓瘤时急性肾损伤的发生率
Nephrol Dial Transplant. 2025 Jan 13. doi: 10.1093/ndt/gfaf004.
3
Value of Reducing Wait Times for Chimeric Antigen Receptor T-Cell Treatment: Evidence From Randomized Controlled Trial Data on Tisagenlecleucel for Diffuse Large B-Cell Lymphoma.嵌合抗原受体 T 细胞治疗等待时间缩短的价值：来自Tisagenlecleucel 治疗弥漫性大 B 细胞淋巴瘤的随机对照试验数据的证据。
Value Health. 2022 Aug;25(8):1344-1351. doi: 10.1016/j.jval.2022.02.007. Epub 2022 Mar 24.
4
Real-World Analysis of Barriers to Timely Administration of Chimeric Antigen Receptor T Cell (CAR T) Therapy in Diffuse Large B-cell Lymphoma.弥漫性大 B 细胞淋巴瘤中嵌合抗原受体 T 细胞（CAR T）治疗及时给药障碍的真实世界分析。
Transplant Cell Ther. 2024 Nov;30(11):1082.e1-1082.e10. doi: 10.1016/j.jtct.2024.09.007. Epub 2024 Sep 11.
5
PD-1 blockade does not improve efficacy of EpCAM-directed CAR T-cell in lung cancer brain metastasis.程序性死亡受体1（PD-1）阻断疗法并不能提高靶向上皮细胞黏附分子（EpCAM）的嵌合抗原受体（CAR）T细胞治疗肺癌脑转移的疗效。
Cancer Immunol Immunother. 2024 Oct 3;73(12):255. doi: 10.1007/s00262-024-03837-9.
6
Fertility and CAR T-cells: Current practice and future directions.生育能力与 CAR T 细胞：当前实践与未来方向。
Transplant Cell Ther. 2022 Sep;28(9):605.e1-605.e8. doi: 10.1016/j.jtct.2022.06.002. Epub 2022 Jun 12.
7
Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy.接受双特异性LV20.19嵌合抗原受体T细胞疗法治疗的患者的患者报告结局和神经毒性标志物。
Commun Med (Lond). 2022 May 12;2(1):49. doi: 10.1038/s43856-022-00116-5. eCollection 2022.
8
Outcomes in patients with multiple myeloma receiving salvage treatment after BCMA-specific CAR-T therapy: A retrospective analysis of LEGEND-2.BCMA 特异性 CAR-T 治疗后接受挽救治疗的多发性骨髓瘤患者的结局：LEGEND-2 的回顾性分析。
Br J Haematol. 2024 May;204(5):1780-1789. doi: 10.1111/bjh.19340. Epub 2024 Feb 18.
9
Label-free in vitro assays predict the potency of anti-disialoganglioside chimeric antigen receptor T-cell products.无标记的体外检测可预测抗神经节苷脂嵌合抗原受体 T 细胞产品的效力。
Cytotherapy. 2023 Jun;25(6):670-682. doi: 10.1016/j.jcyt.2023.01.008. Epub 2023 Feb 26.
10
Serial Evaluation of Preimmunization Antibody Titers in Lymphoma Patients Receiving Chimeric Antigen Receptor T Cell Therapy.嵌合抗原受体 T 细胞治疗后淋巴瘤患者预免疫抗体滴度的连续评估。
Transplant Cell Ther. 2024 Apr;30(4):455.e1-455.e7. doi: 10.1016/j.jtct.2024.02.003. Epub 2024 Feb 10.

本文引用的文献

1
Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network.社区移植与细胞治疗网络中 NHL 患者接受抗 CD19+嵌合抗原受体 T 细胞（CART）治疗的获取障碍
Blood Adv. 2025 Jan 28;9(2):429-435. doi: 10.1182/bloodadvances.2024014171.
2
Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity.真实世界和临床试验中 axicabtagene ciloleucel 治疗大 B 细胞淋巴瘤的结局与种族和民族有关。
Blood. 2024 Jun 27;143(26):2722-2734. doi: 10.1182/blood.2023023447.
3
Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy.
种族和健康社会决定因素对接受 CAR-T 治疗的侵袭性 B 细胞 NHL 患者结局的影响。
Blood Adv. 2024 May 28;8(10):2592-2599. doi: 10.1182/bloodadvances.2023011996.
4
Geographic and Racial Disparities in Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials Access for Diffuse Large B-Cell Lymphoma.嵌合抗原受体 T 细胞和双特异性抗体试验在弥漫性大 B 细胞淋巴瘤中的应用存在地域和种族差异。
Clin Lymphoma Myeloma Leuk. 2024 May;24(5):316-322. doi: 10.1016/j.clml.2024.01.006. Epub 2024 Jan 17.
5
Access to CAR T-cell therapy: Focus on diversity, equity and inclusion.CAR T 细胞治疗的可及性：关注多样性、公平性和包容性。
Blood Rev. 2024 Jan;63:101136. doi: 10.1016/j.blre.2023.101136. Epub 2023 Oct 5.
6
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.阿基仑赛治疗大 B 细胞淋巴瘤的总生存。
N Engl J Med. 2023 Jul 13;389(2):148-157. doi: 10.1056/NEJMoa2301665. Epub 2023 Jun 5.
7
Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.克服复发/难治性弥漫性大 B 细胞淋巴瘤患者接受嵌合抗原受体 T 细胞治疗的转诊障碍。
Transplant Cell Ther. 2023 Jul;29(7):440-448. doi: 10.1016/j.jtct.2023.04.003. Epub 2023 Apr 7.
8
Access to Chimeric Antigen Receptor T Cell Clinical Trials in Underrepresented Populations: A Multicenter Cohort Study of Pediatric and Young Adult Acute Lymphobastic Leukemia Patients.代表性不足人群中嵌合抗原受体 T 细胞临床试验的可及性：儿科和青年急性淋巴细胞白血病患者的多中心队列研究。
Transplant Cell Ther. 2023 Jun;29(6):356.e1-356.e7. doi: 10.1016/j.jtct.2023.03.022. Epub 2023 Mar 24.
9
Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy.列入接受靶向BCMA的商业化嵌合抗原受体T细胞（CAR-T）疗法的复发难治性多发性骨髓瘤患者的临床结局
Bone Marrow Transplant. 2023 Apr;58(4):443-445. doi: 10.1038/s41409-022-01905-1. Epub 2022 Dec 22.
10
Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy.贫困和邻里机会对接受 CD19 导向嵌合抗原受体 T 细胞治疗的儿童结局的影响。
Blood. 2023 Feb 9;141(6):609-619. doi: 10.1182/blood.2022017866.